Obsessive-Compulsive Disorder - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 42
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O7D6AAC79EBEN
Leaflet:

Download PDF Leaflet

Obsessive-Compulsive Disorder - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Obsessive-Compulsive Disorder - Pipeline Review, H2 2016’, provides an overview of the Obsessive-Compulsive Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder
  • The report reviews pipeline therapeutics for Obsessive-Compulsive Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Obsessive-Compulsive Disorder therapeutics and enlists all their major and minor projects
  • The report assesses Obsessive-Compulsive Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Obsessive-Compulsive Disorder Overview
Therapeutics Development
Pipeline Products for Obsessive-Compulsive Disorder - Overview
Obsessive-Compulsive Disorder - Therapeutics under Development by Companies
Obsessive-Compulsive Disorder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Obsessive-Compulsive Disorder - Products under Development by Companies
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
C4X Discovery Holdings PLC
Novartis AG
Omeros Corporation
Obsessive-Compulsive Disorder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
18-MC - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
ADX-71743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluvoxamine maleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Obsessive-Compulsive Disorder - Dormant Projects
Obsessive-Compulsive Disorder - Discontinued Products
Obsessive-Compulsive Disorder - Product Development Milestones
Featured News & Press Releases
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
Aug 02, 2007: Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Obsessive-Compulsive Disorder, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H2 2016
Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H2 2016
Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc., H2 2016
Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Holdings PLC, H2 2016
Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H2 2016
Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Obsessive-Compulsive Disorder - Dormant Projects, H2 2016
Obsessive-Compulsive Disorder - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Obsessive-Compulsive Disorder, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AbbVie Inc.
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
C4X Discovery Holdings PLC
Novartis AG
Omeros Corporation
Skip to top


Ask Your Question

Obsessive-Compulsive Disorder - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: